Kristiyana Kaneva, Medical Director, Oncology Early Development at AbbVie, shared a post on LinkedIn:
“I am happy to share that I have started a new position as a Medical Director, Oncology Early Development at AbbVie this week.
And I am sad to share that I left Tempus AI at the end of last week.
During my almost 5 years at Tempus I experienced an incredible amount of professional growth while building biomarkers alongside some of the brightest humans I have had the privilege of meeting. I felt deep in my core that the work I was doing was meaningful and impactful and allowed me to make a contribution to the oncology field outside of the clinic.
My mentors, Kim Blackwell and Halla Nimeiri, MD, courageous trailblazers and exceptional role models, left a lasting mark on me. My horizons expanded far beyond the medicine and science into a truly cross functional and collaborative, mission driven world. I celebrated Tempus through an IPO. I worked closely with many of the world leaders in the ctDNA space while experiencing end to end development of a tumor-naive MRD assay in colon cancer from a concept to the clinic. Made some forever friends.
And then I felt that the time to pivot to drug development and complete the puzzle is now or never in terms of an overarching career trajectory. I could not think of a better place than OED at Abbvie to start this next chapter and round out my triple threat. Today was my Day 3 and I am overwhelmed with the mentorship as well as kindness and passion of everyone on the team.
I am excited to learn and advance molecules from the preclinical world through proof of concept and early phase clinical trials with this incredible team. I can’t say that I dreamed to become a drug developer when I was a little girl but at some point along the way this dream was born. A midlife crisis can be very powerful. Ready and so grateful for this next challenge.”
